Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.
波士頓，2024年11月26日（GLOBE NEWSWIRE）——開發旨在保持器官功能的實體瘤精準療法的臨床階段生物技術公司Aura Biosciences, Inc.（納斯達克股票代碼：AURA）今天宣佈，首席執行官伊麗莎白·德洛斯皮諾斯博士將於2024年12月3日星期二下午2點35分參加第七屆Evercore ISI HealthConx年度會議的爐邊談話。等。
The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at , where a replay of the webcast will be archived for 90 days following the presentation date.
爐邊談話的網絡直播將在公司網站 「活動與演講」 部分下的 「投資者與媒體」 頁面上播出，網絡直播的重播將在演示日期後的90天內存檔。
About Aura Biosciences
關於奧拉生物科學
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Aura Biosciences是一家處於臨床階段的生物技術公司，專注於開發旨在保持器官功能的實體瘤精準療法。我們的主要候選藥物bel-sar（AU-011）目前處於原發性脈絡膜黑色素瘤的後期開發階段，其他眼部腫瘤適應症和膀胱癌的開發處於早期階段。Aura Biosciences總部位於馬薩諸塞州波士頓。我們的使命是成長爲一家創新的全球腫瘤公司，積極改變患者的生活。
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
欲了解更多信息，請訪問 aurabiosciences.com。在 X（前身爲 Twitter）@AuraBiosciences 上關注我們，然後在 LinkedIn 上訪問我們。
Investor Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
投資者聯繫人：
亞歷克斯·達薩拉
投資者關係和企業傳播主管
IR@aurabiosciences.com
Media Contact:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
媒體聯繫人：
金伯利哈
KKH 顧問
kimberly.ha@kkhadvisors.com
917-291-5744
